414 related articles for article (PubMed ID: 24102379)
21. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
22. Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations.
Mora J; Cascón A; Robledo M; Catala A
Pediatr Blood Cancer; 2006 Nov; 47(6):785-9. PubMed ID: 16304664
[TBL] [Abstract][Full Text] [Related]
23. Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance.
Gómez AM; Soares DC; Costa AAB; Pereira DP; Achatz MI; Formiga MN
Arch Endocrinol Metab; 2019 Jul; 63(4):369-375. PubMed ID: 31365623
[TBL] [Abstract][Full Text] [Related]
24. Novel SDHD germ-line mutations in pheochromocytoma patients.
Neumayer C; Moritz A; Asari R; Weinhäusel A; Hölzenbein T; Kretschmer G; Niederle B; Haas OA
Eur J Clin Invest; 2007 Jul; 37(7):544-51. PubMed ID: 17576205
[TBL] [Abstract][Full Text] [Related]
25. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
Gimenez-Roqueplo AP; Dahia PL; Robledo M
Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
[TBL] [Abstract][Full Text] [Related]
26. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.
de Cubas AA; Leandro-García LJ; Schiavi F; Mancikova V; Comino-Méndez I; Inglada-Pérez L; Perez-Martinez M; Ibarz N; Ximénez-Embún P; López-Jiménez E; Maliszewska A; Letón R; Gómez Graña A; Bernal C; Alvarez-Escolá C; Rodríguez-Antona C; Opocher G; Muñoz J; Megias D; Cascón A; Robledo M
Endocr Relat Cancer; 2013 Aug; 20(4):477-93. PubMed ID: 23660872
[TBL] [Abstract][Full Text] [Related]
27. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.
Oudijk L; de Krijger RR; Rapa I; Beuschlein F; de Cubas AA; Dei Tos AP; Dinjens WN; Korpershoek E; Mancikova V; Mannelli M; Papotti M; Vatrano S; Robledo M; Volante M
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1376-80. PubMed ID: 24684458
[TBL] [Abstract][Full Text] [Related]
28. Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
Oishi Y; Nagai S; Yoshida M; Fujisawa S; Sazawa A; Shinohara N; Nonomura K; Matsuno K; Shimizu C
Endocr J; 2010; 57(8):745-50. PubMed ID: 20505258
[TBL] [Abstract][Full Text] [Related]
29. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B; Schiavi F; Ni Y; Welander J; Patocs A; Ngeow J; Wellner U; Malinoc A; Taschin E; Barbon G; Lanza V; Söderkvist P; Stenman A; Larsson C; Svahn F; Chen JL; Marquard J; Fraenkel M; Walter MA; Peczkowska M; Prejbisz A; Jarzab B; Hasse-Lazar K; Petersenn S; Moeller LC; Meyer A; Reisch N; Trupka A; Brase C; Galiano M; Preuss SF; Kwok P; Lendvai N; Berisha G; Makay Ö; Boedeker CC; Weryha G; Racz K; Januszewicz A; Walz MK; Gimm O; Opocher G; Eng C; Neumann HPH;
JAMA Oncol; 2017 Sep; 3(9):1204-1212. PubMed ID: 28384794
[TBL] [Abstract][Full Text] [Related]
30. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma.
Buffet A; Venisse A; Nau V; Roncellin I; Boccio V; Le Pottier N; Boussion M; Travers C; Simian C; Burnichon N; Abermil N; Favier J; Jeunemaitre X; Gimenez-Roqueplo AP
Horm Metab Res; 2012 May; 44(5):359-66. PubMed ID: 22517557
[TBL] [Abstract][Full Text] [Related]
31. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
Dénes J; Swords F; Rattenberry E; Stals K; Owens M; Cranston T; Xekouki P; Moran L; Kumar A; Wassif C; Fersht N; Baldeweg SE; Morris D; Lightman S; Agha A; Rees A; Grieve J; Powell M; Boguszewski CL; Dutta P; Thakker RV; Srirangalingam U; Thompson CJ; Druce M; Higham C; Davis J; Eeles R; Stevenson M; O'Sullivan B; Taniere P; Skordilis K; Gabrovska P; Barlier A; Webb SM; Aulinas A; Drake WM; Bevan JS; Preda C; Dalantaeva N; Ribeiro-Oliveira A; Garcia IT; Yordanova G; Iotova V; Evanson J; Grossman AB; Trouillas J; Ellard S; Stratakis CA; Maher ER; Roncaroli F; Korbonits M
J Clin Endocrinol Metab; 2015 Mar; 100(3):E531-41. PubMed ID: 25494863
[TBL] [Abstract][Full Text] [Related]
33. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
34. Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas.
Pillai S; Gopalan V; Lam AK
Crit Rev Oncol Hematol; 2017 Aug; 116():58-67. PubMed ID: 28693800
[TBL] [Abstract][Full Text] [Related]
35. Novel Germline
Provenzano A; Chetta M; De Filpo G; Cantini G; La Barbera A; Nesi G; Santi R; Martinelli S; Rapizzi E; Luconi M; Maggi M; Mannelli M; Ercolino T; Canu L
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013579
[TBL] [Abstract][Full Text] [Related]
36. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility.
Astuti D; Hart-Holden N; Latif F; Lalloo F; Black GC; Lim C; Moran A; Grossman AB; Hodgson SV; Freemont A; Ramsden R; Eng C; Evans DG; Maher ER
Clin Endocrinol (Oxf); 2003 Dec; 59(6):728-33. PubMed ID: 14974914
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of Succinate dehydrogenase B (SDHB) immunohistochemistry in guiding mutational screening among patients with pheochromocytoma-paraganglioma syndromes.
Pai R; Manipadam MT; Singh P; Ebenazer A; Samuel P; Rajaratnam S
APMIS; 2014 Nov; 122(11):1130-5. PubMed ID: 24735130
[TBL] [Abstract][Full Text] [Related]
38. Mutations seen among patients with pheochromocytoma and paraganglioma at a referral center from India.
Pai R; Ebenazer A; Paul MJ; Thomas N; Nair A; Seshadri MS; Oommen R; Shanthly N; Devasia A; Rebekah G; Jeyaseelan L; Rajaratnam S
Horm Metab Res; 2015 Feb; 47(2):133-7. PubMed ID: 24977658
[TBL] [Abstract][Full Text] [Related]
39. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.
Crona J; Maharjan R; Delgado Verdugo A; Stålberg P; Granberg D; Hellman P; Björklund P
Fam Cancer; 2014 Mar; 13(1):121-5. PubMed ID: 23743562
[TBL] [Abstract][Full Text] [Related]
40. Universal genetic screening uncovers a novel presentation of an SDHAF2 mutation.
Casey R; Garrahy A; Tuthill A; O'Halloran D; Joyce C; Casey MB; O'Shea P; Bell M
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1392-6. PubMed ID: 24712571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
